192 related articles for article (PubMed ID: 21331473)
1. Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC capsules.
Curatolo W; Liu P; Johnson BA; Hausberger A; Quan E; Vendola T; Vatsaraj N; Foulds G; Vincent J; Chandra R
Pharm Res; 2011 Jul; 28(7):1531-9. PubMed ID: 21331473
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic study of the azithromycin dosage-form-dependent food effect.
Curatolo W; Foulds G; Labadie R
Pharm Res; 2010 Jul; 27(7):1361-6. PubMed ID: 20372991
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo pharmacoscintigraphic evaluation of ibuprofen hypromellose and gelatin capsules.
Cole ET; Scott RA; Cade D; Connor AL; Wilding IR
Pharm Res; 2004 May; 21(5):793-8. PubMed ID: 15180336
[TBL] [Abstract][Full Text] [Related]
4. Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors.
Ouellet D; Grossmann KF; Limentani G; Nebot N; Lan K; Knowles L; Gordon MS; Sharma S; Infante JR; Lorusso PM; Pande G; Krachey EC; Blackman SC; Carson SW
J Pharm Sci; 2013 Sep; 102(9):3100-9. PubMed ID: 23608920
[TBL] [Abstract][Full Text] [Related]
5. Predicting the human in vivo performance of different oral capsule shell types using a novel in vitro dynamic gastric model.
Vardakou M; Mercuri A; Naylor TA; Rizzo D; Butler JM; Connolly PC; Wickham MS; Faulks RM
Int J Pharm; 2011 Oct; 419(1-2):192-9. PubMed ID: 21843611
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability and in vitro oesophageal sticking tendency of hydroxypropyl methylcellulose capsule formulations and corresponding gelatine capsule formulations.
Honkanen O; Laaksonen P; Marvola J; Eerikäinen S; Tuominen R; Marvola M
Eur J Pharm Sci; 2002 Jun; 15(5):479-88. PubMed ID: 12036724
[TBL] [Abstract][Full Text] [Related]
7. The disintegration behaviour of capsules in fed subjects: a comparison of hypromellose (carrageenan) capsules and standard gelatin capsules.
Jones BE; Basit AW; Tuleu C
Int J Pharm; 2012 Mar; 424(1-2):40-3. PubMed ID: 22214655
[TBL] [Abstract][Full Text] [Related]
8. Time domain 1H NMR as a new method to monitor softening of gelatin and HPMC capsule shells.
Kuentz M; Rothenhäusler B; Röthlisberger D
Drug Dev Ind Pharm; 2006; 32(10):1165-73. PubMed ID: 17090439
[TBL] [Abstract][Full Text] [Related]
9. A scintigraphic investigation of the disintegration behaviour of capsules in fasting subjects: a comparison of hypromellose capsules containing carrageenan as a gelling agent and standard gelatin capsules.
Tuleu C; Khela MK; Evans DF; Jones BE; Nagata S; Basit AW
Eur J Pharm Sci; 2007 Mar; 30(3-4):251-5. PubMed ID: 17188473
[TBL] [Abstract][Full Text] [Related]
10. Effect of fill weight, capsule shell, and sinker design on the dissolution behavior of capsule formulations of a weak acid drug candidate BMS-309403.
Wu Y; Zhao F; Paborji M
Pharm Dev Technol; 2003; 8(4):379-83. PubMed ID: 14601962
[TBL] [Abstract][Full Text] [Related]
11. The shell dissolution of various empty hard capsules.
Chiwele I; Jones BE; Podczeck F
Chem Pharm Bull (Tokyo); 2000 Jul; 48(7):951-6. PubMed ID: 10923822
[TBL] [Abstract][Full Text] [Related]
12. Performance qualification of a new hypromellose capsule: part I. Comparative evaluation of physical, mechanical and processability quality attributes of Vcaps Plus, Quali-V and gelatin capsules.
Sherry Ku M; Li W; Dulin W; Donahue F; Cade D; Benameur H; Hutchison K
Int J Pharm; 2010 Feb; 386(1-2):30-41. PubMed ID: 19900518
[TBL] [Abstract][Full Text] [Related]
13. Hard gelatin and hypromellose (HPMC) capsules: estimation of rupture time by real-time dissolution spectroscopy.
El-Malah Y; Nazzal S; Bottom CB
Drug Dev Ind Pharm; 2007 Jan; 33(1):27-34. PubMed ID: 17192248
[TBL] [Abstract][Full Text] [Related]
14. HPMC capsules: current status and future prospects.
Al-Tabakha MM
J Pharm Pharm Sci; 2010; 13(3):428-42. PubMed ID: 21092714
[TBL] [Abstract][Full Text] [Related]
15. The in vitro dissolution of theophylline from different types of hard shell capsules.
Podczeck F; Jones BE
Drug Dev Ind Pharm; 2002 Oct; 28(9):1163-9. PubMed ID: 12455475
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the puncturing properties of gelatin and hypromellose capsules for use in dry powder inhalers.
Birchall JC; Jones BE; Morrissey A; Jones BE
Drug Dev Ind Pharm; 2008 Aug; 34(8):870-6. PubMed ID: 18686093
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and comparison of physicomechanical characteristics of gelatin and hypromellose capsules.
Missaghi S; Fassihi R
Drug Dev Ind Pharm; 2006 Aug; 32(7):829-38. PubMed ID: 16908420
[TBL] [Abstract][Full Text] [Related]
18. Lipid Based Formulations in Hard Gelatin and HPMC Capsules: a Physical Compatibility Study.
Koehl NJ; Shah S; Tenekam ID; Khamiakova T; Sauwen N; Vingerhoets S; Coppenolle H; Holm R
Pharm Res; 2021 Aug; 38(8):1439-1454. PubMed ID: 34378150
[TBL] [Abstract][Full Text] [Related]
19. Influence of capsule shell composition on the performance indicators of hypromellose capsule in comparison to hard gelatin capsules.
Al-Tabakha MM; Arida AI; Fahelelbom KM; Sadek B; Saeed DA; Abu Jarad RA; Jawadi J
Drug Dev Ind Pharm; 2015; 41(10):1726-37. PubMed ID: 25586554
[TBL] [Abstract][Full Text] [Related]
20. Modified conventional hard gelatin capsules as fast disintegrating dosage form in the oral cavity.
Ciper M; Bodmeier R
Eur J Pharm Biopharm; 2006 Feb; 62(2):178-84. PubMed ID: 16260126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
